|
|
|
|
| Register today for the inaugural Advancing RNA Live, happening February 21st! During this discussion, we will identify where the biggest supply gaps for mRNA medicines exist today and how innovators and suppliers can work together to bridge those gaps and improve the availability and quality of raw materials for improved IVT production of mRNA and LNP formulation. This digital event is free to attend thanks to the support of ThermoFisher Scientific. |
|
|
|
|
By AR Welch, editorial and community director, Advancing RNA | Conversations digging into RNA-specific sourcing considerations have been few and far between. Enter Sanofi's Greg Troiano. Together, we delved into the nuances, challenges, and opportunities for growth that currently exist within the mRNA drug substance and drug product (i.e., mRNA-LNP) raw material sourcing worlds. |
|
|
|
By Brent Warner and Blair Madison, Poseida Therapeutics | This article navigates the nomenclature that underlies gene therapy and gene editing technologies and explores the latest advancements in genome medicine. |
|
|
|
mRNA therapeutics present a whole new safety paradigm not seen in vaccine applications. In this segment, Combined Therapeutics CSO Thomas Van Cott, Ph.D., and Omega Therapeutics executive director, process development and analytical sciences, Jeff Atkinson, Ph.D., address the nuances of mRNA therapeutic analytics and assays. |
|
|
|
|
| Streamlining Upstream Plasmid DNA Manufacturing | White Paper | By Kayla J. Spivey, Thermo Fisher Scientific | Explore scalable process workflow solutions available from initial R&D investment to clinical testing and commercialization to meet the shift in demand created by mRNA vaccines. |
|
|
|
| Chromatographic Purification Of Plasmid DNA | Application Note | MilliporeSigma | Widespread application of pDNA in gene therapy is driving increased demand and, as a response, plasmid manufacturing must become more efficient with improved productivity. |
|
|
| Embracing GMP Manufacturing To Meet Pharma’s Future | Article | Nanoform | As pharma companies aim to overcome development obstacles, it is important to incorporate GMP expertise alongside novel technologies that can enhance the properties of APIs and dosage forms. |
|
|
.png){kind=logo}
